What Антимигрен Treats: Main Uses and Benefits

Антимигрен is generally applied as a symptomatic assistance for established acute migraine headaches, including both attacks with and without aura, in adults. This medication is applied to help manage the symptoms of migraine headaches, which are often described as severe and throbbing. It is considered relevant for use when the pain has reached a moderate-to-severe intensity, providing a key therapeutic benefit by assisting with the management of symptoms associated with the acute attack and offering supportive relief from symptoms that interfere with daily functioning.

The medication is used for symptomatic relief across a full cluster of manifestations, including the intense throbbing headache pain, associated sensory issues like photophobia (sensitivity to light) and phonophobia (sensitivity to sound), and autonomic discomfort such as nausea and vomiting. This approach supports patients during difficult episodes by easing distress and contributing to improved day-to-day comfort. The medication is used to ease pronounced symptoms and helps reduce the overall burden of the episodic symptoms.

---

Quick Fact: Relief for Acute Migraine Pain

Property	Description
Therapeutic Role	Management of established acute attacks
Pain Intensity	Moderate-to-severe headache intensity
Associated Symptom Relief	Photophobia, phonophobia, nausea, vomiting
Primary Benefit	Assists with maintaining functional stability

Regulatory References

1. NIH MedlinePlus overview

Population Eligibility Status

Official regulatory documents define strict population eligibility for Антимигрен (Sumatriptan Succinate), focusing primarily on cardiovascular health, hepatic function, and age. The medicine is primarily intended for use in adults (18 to 65 years) and is subject to multiple absolute prohibitions.

Category	Regulatory Status
Standard Use Eligibility	Adults aged 18 to 65 years.
Not Recommended	Patients under 18 and those over 65 (due to limited or unestablished clinical experience).

Absolute Contraindications

Use is formally contraindicated (prohibited) in populations with specific pre-existing conditions, including:

• Ischemic heart disease (e.g., angina, history of myocardial infarction).
• Uncontrolled hypertension or coronary artery vasospasm.
• History of stroke or transient ischemic attack (TIA).
• Severe hepatic impairment.
• Wolff-Parkinson-White syndrome or similar cardiac conduction abnormalities.

Additionally, eligibility is restricted based on recent medication use; the drug is prohibited within 24 hours of taking an ergotamine or another triptan, and within two weeks of using a Monoamine Oxidase-A Inhibitor (MAOI). Use during pregnancy is restricted, only permitted when the benefit to the mother is judged to outweigh the potential risk, and breastfeeding requires a 12-hour interruption post-treatment.

Interactions with other medicines and products

This section details officially documented interactions and constraints based on regulatory labeling for antimigraine drugs.

Pharmacokinetic and Pharmacodynamic Constraints

Co-administration of Antimigrene with certain substances is restricted due to two primary concerns: the risk of significantly altered drug exposure and the potential for additive effects on the body.

Constraint Type	Interacting Substance/Class	Resulting Restriction
Contraindicated Combinations	Strong CYP3A4 Inhibitors, MAO Inhibitors, Other 5-HT1 Agonists, Ergot-type Medications	Use is absolutely forbidden due to increased toxicity or vasospasm risk.
Exposure Modification	Moderate CYP3A4 Inhibitors, BCRP/P-gp Inhibitors, Propranolol	Requires a mandated dose reduction of Antimigrene or avoidance of the combination.
Pharmacodynamic Overlap	SSRIs, SNRIs	Concomitant use requires caution due to the potential for Serotonin Syndrome.
Reduced Efficacy Risk	Strong CYP3A4 Inducers (e.g., Rifampin)	Concomitant use is discouraged due to decreased Antimigrene concentration and loss of effect.

Timing and Population Considerations

Specific rules govern dosing intervals. For example, a subsequent dose of a Triptan must be separated by at least 2 hours from the initial dose, and other Triptans or Ergot derivatives must be separated by 24 hours. In patients with severe hepatic or renal impairment, a lower recommended dose may be necessary to compensate for reduced drug clearance.

Selective Agonism and Vascular Tone Modulation

The drug's primary action is the selective agonism of 5-HT1B serotonin receptors found on the cranial blood vessels. Activating these receptors initiates a process of vasoconstriction, which reverses the pathological dilation of certain arteries. This mechanism modulates the vascular tone pathway, influencing the state of the head's circulation.

---

Neural Pathway and Inflammation Control

Concurrently, the drug engages 5-HT1D receptors located on the peripheral nerve endings of the trigeminal system. This interaction causes a functional inhibition, reducing the release of pro-inflammatory neuropeptides (such as CGRP) and the chemical component of neurogenic inflammation. This targeted modulation of the neural pathway modifies early molecular steps, influencing downstream signaling.

The administration of Антимигрен (Sumatriptan Succinate) follows established protocols that define its role strictly in the acute, intermittent management of established migraine attacks, and it is not intended for preventative therapy. The approved method of administration is the oral route, where the film-coated tablet must be swallowed whole with water. This medication may be taken either with or without food.

The standard adult dosing regimen requires a single dose of 50 mg or 100 mg to be administered as soon as possible after the onset of the headache. Approved strengths also include 25 mg. Should migraine symptoms recur after initial relief, a second oral dose may be taken, provided a minimum interval of two hours has passed since the first administration. The total dose administered must not exceed 200 mg within any 24-hour period. If the initial dose provides no response to a particular attack, standard guidelines indicate that a second dose should not be taken for that same episode.

The overall use of this product is constrained by frequency limits, as the safety of treating an average of more than four headaches in a 30-day period has not been established. Specific adjustments to the regimen are required for certain patient groups: for those with mild to moderate hepatic impairment, the maximum single dose is restricted to 50 mg. Furthermore, the medication is not generally recommended for use in patients under 18 or those over 65 due to limited clinical experience.

Research Evidence: Overview of Trials

Research on Антимигрен (a specific triptan) centers on its use for the acute treatment of moderate to severe migraine attacks. The core clinical data are drawn from double-blind, randomized, placebo-controlled trials involving adult patients who meet criteria for migraine with or without aura. The primary focus of these studies is typically the pain-free response and the relief of associated symptoms.

---

Efficacy Findings

• Pain-Free Response: Trials investigated the proportion of patients who achieved a pain-free status two hours after administration, a standard endpoint in acute migraine research. Results consistently show that the drug, across its evaluated doses (e.g., 50 mg and 100 mg), is associated with a higher rate of two-hour pain freedom compared to placebo.
• Relief of Associated Symptoms: Research also documented a reduction in migraine-associated symptoms, such as nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound) following the drug's administration.
• Sustained Effect: Follow-up data explored the sustained pain-free status, meaning the patient remained pain-free without the headache recurring within 24 hours of the initial dose.

---

Factors Influencing Outcomes

Clinical analyses have investigated how different factors may relate to the outcome of the acute treatment:

Factor	Trial Observation
Timing of Treatment	Treatment initiated during the mild pain phase of an attack was observed to correlate with higher rates of pain-free response compared to treatment initiated during moderate or severe pain.
Migraine Subtype	Subgroup analyses suggest that the drug's efficacy may vary slightly between attacks with aura versus attacks without aura.

Pharmacological Studies

Pharmacokinetics studies have evaluated the drug's absorption profile and the timing of initial observed effects following administration. The drug is classified as a selective serotonin receptor agonist, which is the specific class of medication most frequently studied for the acute management of migraine.

Key Studies & References

1. Treatments for migraine | Information for the public | Headaches in over 12s: diagnosis and management | NICE Clinical Guideline CG150
2. Label: SUMATRIPTAN tablet - DailyMed (FDA-Approved Labeling)

Common questions about Антимигрен (FAQ)

Q: What should I know about taking this medicine if I drink alcohol?

Official warnings state that drinking excessive amounts of alcohol while taking this medicine may increase the risk of a very rare but serious medical condition known as lactic acidosis. For this reason, official product information includes a cautionary statement regarding excessive alcohol intake during treatment.

---

Q: Does this medicine cause side effects like sleepiness or fatigue?

Official product information notes that certain serious side effects, such as lactic acidosis, may involve non-specific symptoms including severe tiredness (fatigue) or sleepiness (somnolence). Additionally, tiredness or weakness (asthenia) is also listed as a common side effect reported in clinical trials for immediate-release formulations. If any severe or concerning symptoms occur, review the full safety information or consult a healthcare professional.

---

Q: Is this medicine safe to take long-term, for years?

Studies and regulatory documents indicate that the long-term use of this medicine may be associated with decreased levels of Vitamin B12. Regulatory labeling indicates the potential need for regular monitoring of Vitamin B12 levels and blood parameters during long-term use.

---

Q: Can children 2 years old use this medicine?

This medicine is approved for use in pediatric patients who are 10 years of age and older for the treatment of type 2 diabetes. Official labeling specifies that it is either contraindicated or not recommended for use in children who are younger than 10 years old.

---

Q: What is the proper way to take this medicine, such as with food?

The administration instructions depend on the specific formulation being used. Immediate-release tablets are generally taken with meals. For extended-release tablets, official guidelines often recommend taking them once daily with the evening meal. Patients should confirm the specific instructions for their formulation with a healthcare provider or refer to the product leaflet.

---

Q: What happens if I miss a dose of this medicine?

If a dose is missed, official product information advises against taking two doses at the same time or on the same day to make up for the missed one. The labeling specifies that the usual practice is to resume by taking the next scheduled dose at the customary time, rather than taking a double dose.

---

Q: What should I avoid when I'm taking this medicine, besides alcohol?

It is associated with contraindications, including severe kidney impairment (based on eGFR levels) and acute or chronic metabolic acidosis. Regulatory documents also state that temporary discontinuation may be required for certain imaging procedures involving intravenous iodinated contrast agents, based on kidney function.

How to Store and Dispose of Антимигрен?

The official storage conditions for Антимигрен (Sumatriptan Succinate oral tablets) are established to maintain product stability and potency. The tablets must be stored at controlled room temperature, defined as between 2C and 30C (36F and 86F).

Mandatory Protection and Handling

Requirement	Constraint
Temperature Restriction	Do not freeze the product.
Environmental Protection	Must be kept away from excessive heat, moisture, and light.
Container Integrity	Store the tablets in a well-closed container.

The medication must be stored out of the sight and reach of children, as required for all prescription products. For disposal, unused or outdated medication should be discarded according to the guidance of a healthcare professional or pharmacist. Regulatory documents advise against disposing of the medicine by flushing it down a toilet or sink.